Ceftriaxone injection is a third-generation cephalosporin antibiotic used to treat severe bacterial infections, including meningitis, pneumonia, septicaemia and some sexually transmitted infections. It can be given by intramuscular or intravenous injection, depending on the condition and preparation used. Because ceftriaxone is a broad-spectrum antibiotic requiring careful dosing and administration, treatment should remain under qualified medical supervision.
What ceftriaxone injection does
Ceftriaxone works as an antibacterial medicine. Médecins Sans Frontières classifies it as a third-generation cephalosporin and recommends it for a range of serious bacterial infections.
Conditions listed in the MSF guidance include:
- Septicaemia
- Meningitis
- Pneumonia
- Typhoid fever
- Shigellosis
- Leptospirosis
- Tick-borne relapsing fever
- Pyelonephritis
- Neurosyphilis
- Gonococcal cervicitis
- Gonococcal urethritis
- Gonococcal conjunctivitis
- Chancroid
For gonococcal cervicitis and urethritis, ceftriaxone is used together with treatment for chlamydia, except in neonates.
This wide range of uses helps explain why ceftriaxone is frequently encountered in hospitals and emergency care. That usefulness comes with a responsibility: it should not become an automatic treatment for every fever, cough or suspected infection.
The World Health Organization groups antibiotics according to its AWaRe framework to encourage appropriate prescribing and reduce antimicrobial resistance. The framework distinguishes Access, Watch and Reserve antibiotics according to resistance risk and stewardship needs.
For Tanzania and the wider East African region, that stewardship principle matters wherever clinicians are treating severe infection while also trying to preserve the effectiveness of antibiotics for future patients.
Available strengths and how ceftriaxone is administered
MSF lists ceftriaxone as powder for injection supplied in:
- 250 mg vials
- 1 g vials
The powder must be reconstituted before administration.
For intramuscular injection, ceftriaxone may be dissolved using a solvent containing lidocaine. A ceftriaxone solution prepared with this lidocaine-containing solvent must not be administered intravenously.
For slow intravenous injection, the powder is dissolved in water for injection and administered over approximately three minutes.
For intravenous infusion, administration takes approximately 30 minutes. The medicine may be diluted in 0.9% sodium chloride or 5% glucose.
For children weighing less than 20 kg, MSF specifies dilution of each intravenous infusion dose in 5 ml/kg of 0.9% sodium chloride or 5% glucose.
For children weighing 20 kg or more and adults, each dose may be diluted in a 100 ml bag of 0.9% sodium chloride or 5% glucose.
These preparation differences are not minor technical details. Using the wrong solvent or route can create avoidable risks, which is one reason ceftriaxone injections should be prepared and administered by trained health professionals.
Visit the official MSF medical guideline at: https://medicalguidelines.msf.org/en/viewport/EssDr/english/ceftriaxone-injectable-16682532.html
Ceftriaxone dosage for severe bacterial infections
The correct dose depends on the patient’s age, weight, infection and clinical response.
For severe bacterial infections, MSF gives the following guidance:
- Children aged one month and above weighing under 50 kg: 50 to 100 mg/kg once daily, with a maximum dose of 4 g.
- Children weighing 50 kg or more and adults: 1 to 2 g once daily.
- For meningitis and typhoid fever, doses may increase to 2 g twice daily or 4 g once daily.
Treatment duration varies according to the infection and how the patient responds.
MSF advises switching from injectable ceftriaxone to oral treatment as soon as clinically appropriate. The oral antibiotic selected will depend on the infection being treated.
That step-down approach has practical value. Patients who no longer require injectable therapy may avoid unnecessary prolonged injections, while healthcare facilities can reserve intravenous treatment for those who genuinely need it.
Antibiotic selection should still follow the treating clinician’s diagnosis and local treatment protocols rather than the dose list alone.
Ceftriaxone doses for gonorrhoea and chancroid
For gonococcal cervicitis, gonococcal urethritis and chancroid, MSF provides different single-dose regimens.
For gonococcal cervicitis and urethritis:
- Child weighing under 45 kg: 125 mg intramuscularly as a single dose.
- Child weighing 45 kg or more and adult: 500 mg intramuscularly as a single dose.
For chancroid:
- Child weighing 45 kg or more and adult: 250 mg intramuscularly as a single dose.
Gonococcal conjunctivitis requires separate dosing:
- Neonate: 50 mg/kg intramuscularly as a single dose, up to a maximum of 125 mg.
- Adult: 1 g intramuscularly as a single dose.
Because sexually transmitted infections can require treatment for more than one organism, patients should follow the complete regimen prescribed rather than assuming a ceftriaxone injection alone covers every possible infection.
Contraindications and patients who require extra care
Ceftriaxone should not be administered to people with an allergy to cephalosporins or penicillins because cross-sensitivity can occur.
MSF also advises against ceftriaxone in neonates with jaundice because of the risk of bilirubin encephalopathy.
Newborns receiving calcium gluconate should not receive ceftriaxone because ceftriaxone-calcium salts may precipitate in the lungs and kidneys.
Patients with liver or kidney impairment require additional caution.
In severe renal impairment, MSF advises reducing the dose to a maximum of:
- 50 mg/kg per day, or
- 2 g per day intravenously.
The medicine must also not be mixed with calcium-containing solutions such as Ringer lactate because particles may form.
These restrictions underline an important point for patients: knowing the name of an antibiotic does not make self-treatment safe. Kidney function, liver function, allergy history, age, other medicines and the suspected organism can all influence treatment decisions.
Possible side effects of ceftriaxone
Ceftriaxone can cause adverse effects ranging from gastrointestinal symptoms to severe allergic reactions.
MSF lists possible effects including:
- Gastrointestinal disturbances
- Liver dysfunction
- Anaemia
- Leucopenia
- Neutropenia
- Kidney dysfunction
- Allergic reactions
- Severe skin reactions, including Stevens-Johnson syndrome
Patients receiving treatment should promptly report symptoms such as breathing difficulty, facial swelling, widespread rash or severe skin changes to medical staff.
Pregnancy itself is not listed by MSF as a contraindication to ceftriaxone.
Breast-feeding is also not listed as a contraindication.
That does not remove the need for medical assessment. Pregnant or breastfeeding patients should still tell the prescribing clinician so the infection, dose and overall treatment plan can be assessed properly.
Important preparation and injection precautions
Some of ceftriaxone’s most significant safety instructions concern preparation.
MSF advises that:
- Ceftriaxone prepared with lidocaine-containing solvent for intramuscular injection must never be given intravenously.
- Ceftriaxone intended for intravenous administration should be dissolved in water for injection.
- Ceftriaxone should not be mixed with calcium-containing fluids.
- Ceftriaxone should not be mixed with another medicine in the same syringe or infusion.
Large doses also affect the recommended route.
When an intramuscular dose exceeds 1 g, MSF advises dividing it equally between two injection sites, with one injection in each buttock.
Doses greater than 2 g should be administered by intravenous infusion only.
For healthcare workers, these instructions reinforce why correct reconstitution and route checking are part of medication safety rather than administrative routine.
For patients, the practical message is simpler: ceftriaxone should be administered in an appropriate healthcare setting by someone trained to prepare injectable medicines correctly.
Why responsible ceftriaxone use matters in East Africa
Broad-spectrum antibiotics have transformed treatment of serious infections across Africa, especially where clinicians must begin treatment rapidly before detailed laboratory results become available.
Yet their strength can create another problem when antibiotics are used unnecessarily or incorrectly.
WHO developed the AWaRe antibiotic classification in 2017 specifically to support antibiotic stewardship, monitoring and efforts to slow antimicrobial resistance. The system has continued to be updated as resistance has become an increasingly important public-health challenge.
That matters for Tanzania because resistance can make common infections harder and more expensive to treat. A medicine that works reliably today may become less effective when bacterial resistance spreads through repeated inappropriate exposure.
Patients can support responsible use by avoiding several common mistakes:
- Do not obtain ceftriaxone injections simply because a previous illness improved after receiving one.
- Do not pressure healthcare workers for injectable antibiotics when they recommend another treatment.
- Do not stop a prescribed treatment course or change doses without medical advice.
- Do not share antibiotics with another person.
- Seek proper diagnosis when symptoms persist or worsen.
A powerful antibiotic is most valuable when it remains effective.
Storage and handling
Ceftriaxone should be stored below 25°C.
Once the medicine has been reconstituted, MSF advises using the solution immediately.
Storage requirements matter in warm climates. Clinics, pharmacies and health facilities need suitable medicine-storage systems so temperature-sensitive products remain within recommended conditions before preparation.
Patients receiving ceftriaxone generally should not be expected to prepare or store reconstituted injection solutions themselves.
The medicine is intended for prescription use under medical supervision.
What patients should remember
Ceftriaxone injection is an important treatment for serious bacterial infections, but its dose, solvent and route vary considerably between patients and conditions. Allergy history, kidney or liver impairment, neonatal jaundice and concurrent calcium treatment can all change whether or how the medicine should be used.
Anyone prescribed ceftriaxone should follow the treating clinician’s instructions rather than using general dosing information for self-treatment. Responsible prescribing and correct administration protect both the individual patient and the long-term effectiveness of antibiotics.
